Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial.

Lustig RH, Hinds PS, Ringwald-Smith K, Christensen RK, Kaste SC, Schreiber RE, Rai SN, Lensing SY, Wu S, Xiong X

The Journal of clinical endocrinology and metabolism1 Jun 2003Cited by 181 (Europe PMC)

PMID12788859DOI10.1210/jc.2002-030003PepBankPUB-12788859

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In children with hypothalamic obesity, weight increased by 1.6 +/- 0.6 kg with octreotide versus 9.1 +/- 1.7 kg with placebo (P < 0.001).
In plain wordsIn children with hypothalamic obesity, octreotide reduced weight gain compared with placebo.
Peptide
Octreotide
Outcome
DecreaseWeight change
Study
n = 18
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
5-15 microg/kg per day · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Weight change, mean
1.6 kg
octreotide group; SEM 0.6
Weight change, mean
9.1 kg
placebo group; SEM 1.7
Source sentences
Summary
With octreotide, Delta weight (mean +/- SEM) was +1.6 +/- 0.6 vs. +9.1 +/- 1.7 kg for placebo (P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We report the results of a randomized, double-blind, placebo-controlled trial of octreotide therapy for pediatric hypothalamic obesity.
Summary · context
Eighteen subjects [weight, 100.6 +/- 5.6 kg; body mass index (BMI), 37.1 +/- 1.3 kg/m(2)] received octreotide (5-15 microg/kg x d s.c.) or placebo for 6 months.
Report a problemFND-1278885901
02HumanRandomized controlled trialEfficacy outcome
In children with hypothalamic obesity, BMI changed by -0.2 +/- 0.2 versus +2.2 +/- 0.5 kg/m(2) with placebo (P < 0.001).
In plain wordsIn children with hypothalamic obesity, octreotide reduced BMI change compared with placebo.
Peptide
Octreotide
Outcome
DecreaseBMI change
Study
n = 18
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
5-15 microg/kg per day · subcutaneous · 6 monthsAs given in this study (human).
Measurements
BMI change, mean
−0.2 kg/m(2)
octreotide group; SEM 0.2
BMI change, mean
2.2 kg/m(2)
placebo group; SEM 0.5
Source sentences
Summary
Delta BMI was -0.2 +/- 0.2 vs. +2.2 +/- 0.5 kg/m(2), respectively (P < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
With octreotide, Delta weight (mean +/- SEM) was +1.6 +/- 0.6 vs. +9.1 +/- 1.7 kg for placebo (P < 0.001).
Summary · context
We report the results of a randomized, double-blind, placebo-controlled trial of octreotide therapy for pediatric hypothalamic obesity.
Summary · context
Eighteen subjects [weight, 100.6 +/- 5.6 kg; body mass index (BMI), 37.1 +/- 1.3 kg/m(2)] received octreotide (5-15 microg/kg x d s.c.) or placebo for 6 months.
Report a problemFND-1278885902
03HumanRandomized controlled trialEfficacy outcome
In children with hypothalamic obesity, insulin response changed by -417 +/- 304 pM with octreotide versus +216 +/- 215 with placebo (P = 0.034).
In plain wordsIn children with hypothalamic obesity, octreotide reduced the insulin response to glucose compared with placebo.
Peptide
Octreotide
Outcome
DecreaseOGTT insulin response change
Study
n = 18
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5-15 microg/kg per day · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Delta insulin response (peak - basal), mean
−417 pM
octreotide group; SEM 304
Delta insulin response (peak - basal), mean
216 pM
placebo group; SEM 215
Source sentences
Summary
OGTT documented Delta insulin response (peak - basal) of -417 +/- 304 pM after octreotide vs. +216 +/- 215 pM after placebo (P = 0.034).
2 context sentences(design, population, supporting numbers)
Summary · context
We report the results of a randomized, double-blind, placebo-controlled trial of octreotide therapy for pediatric hypothalamic obesity.
Summary · context
Eighteen subjects [weight, 100.6 +/- 5.6 kg; body mass index (BMI), 37.1 +/- 1.3 kg/m(2)] received octreotide (5-15 microg/kg x d s.c.) or placebo for 6 months.
Report a problemFND-1278885903
04HumanRandomized controlled trialEfficacy outcome
In children with hypothalamic obesity, parent-reported physical activity improved with octreotide but not placebo (P = 0.03).
In plain wordsIn children with hypothalamic obesity, parents reported improved activity with octreotide but not placebo.
Peptide
Octreotide
Outcome
Direction not reportedParent-reported physical activity
Study
n = 18
Comparator
Placebo
Outcome group
Exercise and physical function · Metabolic and weight
Studied dose
5-15 microg/kg per day · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Improvement in physical activity by parent report was noted with octreotide, but not placebo (P = 0.03).
2 context sentences(design, population, supporting numbers)
Summary · context
We report the results of a randomized, double-blind, placebo-controlled trial of octreotide therapy for pediatric hypothalamic obesity.
Summary · context
Eighteen subjects [weight, 100.6 +/- 5.6 kg; body mass index (BMI), 37.1 +/- 1.3 kg/m(2)] received octreotide (5-15 microg/kg x d s.c.) or placebo for 6 months.
Report a problemFND-1278885904
05HumanNon-randomized trialSafety outcome
In children treated for hypothalamic obesity, complications and adverse events were mild and self-limited.
In plain wordsIn children treated for hypothalamic obesity, complications and side effects were mild and self-limited.
Peptide
Octreotide
Outcome
Not applicableComplications and adverse event severity
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
5-15 microg/kg per day · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Complications and adverse events were mild and self-limited.
2 context sentences(design, population, supporting numbers)
Summary · context
We report the results of a randomized, double-blind, placebo-controlled trial of octreotide therapy for pediatric hypothalamic obesity.
Summary · context
Eighteen subjects [weight, 100.6 +/- 5.6 kg; body mass index (BMI), 37.1 +/- 1.3 kg/m(2)] received octreotide (5-15 microg/kg x d s.c.) or placebo for 6 months.
Report a problemFND-1278885906
06HumanObservational studyEfficacy outcome
In children receiving octreotide for hypothalamic obesity, quality-of-life changes correlated positively with insulin-response changes (P = 0.041).
In plain wordsIn children receiving octreotide, quality-of-life changes were positively linked to insulin-response changes.
Peptide
Octreotide
Outcome
Not applicableQuality of life correlation with insulin response
Study
n: not reported in source
Outcome group
Quality of life · Whole body
Studied dose
5-15 microg/kg per day · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
For the octreotide group, changes in quality of life positively correlated with changes in insulin response (P = 0.041).
2 context sentences(design, population, supporting numbers)
Summary · context
We report the results of a randomized, double-blind, placebo-controlled trial of octreotide therapy for pediatric hypothalamic obesity.
Summary · context
Eighteen subjects [weight, 100.6 +/- 5.6 kg; body mass index (BMI), 37.1 +/- 1.3 kg/m(2)] received octreotide (5-15 microg/kg x d s.c.) or placebo for 6 months.
Report a problemFND-1278885905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.